NTCP抑制剂Myrcludex B的临床疗效

StephenW

Clinical effects of NTCP-inhibitor myrcludex B
Dongliang Cheng  1 , Bing Han  1 , Wei Zhang  1 , Wei Wu  1
Affiliations
Affiliation

    1
    School of Pharmacy, Guilin Medical University, Guilin, Guangxi, China.

    PMID: 33599010 DOI: 10.1111/jvh.13490

Abstract

With extensive research on the pathogenesis and treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, the current treatment of interferon and nucleoside or nucleotide analogues provides reasonable control of viral replication in chronic hepatitis B (CHB). However, drug resistance may occur as a result of long-term treatment, and continuous covalently closed circular DNA (cccDNA) can cause disease relapse after drug withdrawal. Therefore, there is an urgent need for safe and effective antiviral drugs or methods to treat HBV and HDV infections. Myrcludex B is the first entry inhibitor that can inactivate HBV and HDV receptors, compete with HBV for the sodium-taurocholate co-transporting polypeptide, which has been identified as the bona fide receptor for HBV and HDV, block HBV infection in hepatocytes, and participate in HBV transcriptional suppression. Myrcludex B plays an important role in the inhibition of HBV replication and is a potential drug for phase III clinical trials. In this article, we review the progress on the efficacy and clinical application of myrcludex B in recent years.

Keywords: Myrcludex B; clinical application; hepatitis B virus.

StephenW

NTCP抑制剂Myrcludex B的临床疗效
程东良1，丙寒1，张伟1，吴武1
隶属关系
联系

    1个
    桂林医科大学药学院，广西桂林。

    PMID：33599010 DOI：10.1111 / jvh.13490

抽象的

随着对乙型肝炎病毒（HBV）和丙型肝炎病毒（HDV）感染的发病机理和治疗的广泛研究，目前对干扰素和核苷或核苷酸类似物的治疗为慢性乙型肝炎（CHB）的病毒复制提供了合理的控制。但是，长期治疗可能会导致耐药性，并且连续共价闭合的环状DNA（cccDNA）可能导致停药后疾病复发。因此，迫切需要安全有效的抗病毒药物或方法来治疗HBV和HDV感染。 Myrcludex B是第一种可灭活HBV和HDV受体，与HBV竞争牛磺胆酸钠共转运多肽的进入抑制剂，后者已被确定为HBV和HDV的真正受体，可阻断肝细胞中的HBV感染并参与在HBV转录抑制中。 Myrcludex B在抑制HBV复制中起重要作用，并且是III期临床试验的潜在药物。在本文中，我们回顾了myrcludex B在近年来的疗效和临床应用方面的进展。

关键字：Myrcludex B;临床应用；乙型肝炎病毒。